Ophthalmic Clinical Trials Market Size, Share & Trends Analysis Report By Product (Devices, Drugs), By Phase (Discovery Phase, Preclinical Phase, Clinical Phase), By Indication, By Sponsor Type, By Region, And Segment Forecasts, 2023 - 2030

Ophthalmic Clinical Trials Market Size, Share & Trends Analysis Report By Product (Devices, Drugs), By Phase (Discovery Phase, Preclinical Phase, Clinical Phase), By Indication, By Sponsor Type, By Region, And Segment Forecasts, 2023 - 2030


Ophthalmic Clinical Trials Market Growth & Trends


The global ophthalmic clinical trials market size is expected to reach USD 2.5 billion by 2030 at a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Technological developments and a rising need for more efficient eye disease treatments are driving the market for ophthalmology clinical trials to expand quickly. Pharmaceutical firms, medical equipment producers, and Contract Research Organizations (CROs) are a few of the major contributors to this sector.

The rising incidence of eye conditions, including glaucoma, macular degeneration, and diabetic retinopathy, is driving the industry. As the global population ages and eye illnesses become more common, the market for ophthalmology clinical trials is further anticipated to grow in the coming years. Additionally, developments in genetic research and personalized medicine are likely to spur innovation in this area, creating more specialized and efficient treatments for eye illnesses.

The demand for clinical trials will rise due to the increasing focus of ophthalmic researchers to develop and market novel ocular medicines. Furthermore, the initiatives adopted to fulfill the unmet needs in developing economies regarding rare ocular conditions are anticipated to support the growth of the ophthalmology clinical trials market. For instance, nearly 2.2 billion people are estimated to have separation or close-up vision impairment disorders, and of these, at least half, or 1 billion cases, can be avoided with the aid of appropriate treatment, according to the World Health Organization's October 2021 report on visually impaired people's impairment.

The COVID-19 pandemic has significantly impacted the ophthalmology clinical trials market. Clinical trials have been hampered by the epidemic, which has delayed the start of new trials and slowed patient enrollment. Additionally, several clinical study locations had to close, significantly reducing patient visits and data collecting. The epidemic has hastened the deployment of remote and virtual clinical trial technology, allowing for the continuation of ongoing trials and the start of new ones. Some of the difficulties brought on by the pandemic, including travel limitations and social seclusion requirements, have been mitigated partly by adopting these technologies.

Ophthalmic Clinical Trials Market Highlights
  • The drug segment accounted for the largest share of 75.5% in 2022. The segment dominated the market owing to the growing demand for innovative and efficient drug therapies for various eye ailments
  • The Glaucoma segment is expected to witness the highest CAGR of 7.3% during the analysis timeframe. The increase in collaboration and partnerships among the key players for developing novel glaucoma products spurs the segment’s growth
  • The clinical phase segment dominated the market in 2022 with a revenue share of 79.4%. Increasing investments in R&D by the government, as well as private entities for the conduct of clinical studies, drives the segment’s growth
  • The pharmaceutical/biopharmaceutical companies segment dominated the market in 2022 with a revenue share of 41.8%. The major sponsors of ophthalmology clinical trials are pharmaceutical and biopharmaceutical companies since they have the resources and knowledge to create and commercialize novel treatments
  • Asia Pacific is anticipated to register a lucrative CAGR of 7.2% during the analysis period. This is primarily due to a huge patient pool willing to undergo clinical trials. Furthermore, the cost-effective nature of clinical trials across developing economies such as India has further attracted Western countries to conduct clinical research, thereby boosting the region’s growth in the ophthalmic clinical trials market
  • Please note The report will be delivered in 3-8 business days upon order notification.


    Chapter 1. Research Methodology And Scope
    1.1. Market Segmentation & Scope
    1.1.1. Segment Definitions
    1.1.2. Product
    1.1.3. Indication
    1.1.4. Phase
    1.1.5. Sponsor Type
    1.2. Regional Scope
    1.3. Estimates And Forecast Timeline
    1.4. Objectives
    1.4.1. Objective - 1
    1.4.2. Objective - 2
    1.4.3. Objective - 3
    1.5. Research Methodology
    1.6. Information Procurement
    1.6.1. Purchased Database
    1.6.2. GVR’s Internal Database
    1.6.3. Secondary Sources
    1.6.4. Primary Research
    1.7. Information Or Data Analysis
    1.7.1. Data Analysis Models
    1.8. Market Formulation & Validation
    1.9. Model Details
    1.9.1. Commodity Flow Analysis
    1.9.2. Parent Market Analysis
    1.10. List Of Secondary Sources
    1.11. List Of Abbreviations
    Chapter 2. Executive Summary
    2.1. Market Outlook
    2.2. Segment Outlook
    2.3. Competitive Insights
    Chapter 3. Ophthalmic Clinical Trials Market Variables, Trends & Scope
    3.1. Market Lineage Outlook
    3.1.1. Parent Market Outlook
    3.1.2. Related/Ancillary Market Outlook
    3.2. Market Dynamics
    3.2.1. Market Driver Analysis
    3.2.1.1. Increasing Partnerships Between CROs And Drug Development Companies To Boost The Market Growth
    3.2.1.2. Growing Research Funding Pertaining To Ocular Therapeutics Is Another Prominent Factor Supporting The Growth Of The Ophthalmic Clinical Trials Market.
    3.2.1.3. Technological Innovations Pertaining to Ophthalmic Research to Boost The Market Growth
    3.2.2. Market Restraint Analysis
    3.2.2.1. Low Barriers to Market Penetration Have Resulted In Pricing Pressure
    3.2.2.2. Challenges Related to Quality Control
    3.3. Ophthalmic Clinical Trials Market Analysis Tools
    3.3.1. Industry Analysis - Porter’s
    3.3.1.1. Supplier Power
    3.3.1.2. Buyer Power
    3.3.1.3. Substitution Threat
    3.3.1.4. Threat Of New Entrant
    3.3.1.5. Competitive Rivalry
    3.3.2. PESTEL Analysis
    3.3.3. COVID-19 Impact Analysis
    Chapter 4. Ophthalmic Clinical Trials Market: Product Estimates & Trend Analysis
    4.1. Ophthalmic Clinical Trials Market, By Product: Segment Dashboard
    4.2. Ophthalmic Clinical Trials Market, By Product: Movement Analysis
    4.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Product, 2018 - 2030
    4.3.1. Devices
    4.3.1.1. Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    4.3.1.2. Surgical & Diagnostics Devices
    4.3.1.2.1. Surgical & Diagnostics Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    4.3.1.3. Vision Care Devices
    4.3.1.3.1. Vision Care Devices Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    4.3.2. Drugs
    4.3.2.1. Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    4.3.2.2. OTC Drugs
    4.3.2.2.1. OTC Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    4.3.2.3. Prescription Drugs
    4.3.2.3.1. Prescription Drugs Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    Chapter 5. Ophthalmic Clinical Trials Market: Indication Estimates & Trend Analysis
    5.1. Ophthalmic Clinical Trials Market, By Indication: Segment Dashboard
    5.2. Ophthalmic Clinical Trials Market, By Indication: Movement Analysis
    5.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030
    5.3.1. Macular Degeneration
    5.3.1.1. Macular Degeneration Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.2. Glaucoma
    5.3.2.1. Glaucoma Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.3. Dry Eye Disease
    5.3.3.1. Dry Eye Disease Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.4. Retinopathy
    5.3.4.1. Retinopathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.5. Uveitis
    5.3.5.1. Uveitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.6. Macular Edema
    5.3.6.1. Macular Edema Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.7. Blepharitis
    5.3.7.1. Blepharitis Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.8. Cataract
    5.3.8.1. Cataract Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.9. Optic Neuropathy
    5.3.9.1. Optic Neuropathy Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    5.3.10. Others
    5.3.10.1. Others Ophthalmic Clinical Trials Market, 2018 to 2030 (USD Million)
    Chapter 6. Ophthalmic Clinical Trials Market: Phase Estimates & Trend Analysis
    6.1. Ophthalmic Clinical Trials Market, By Phase: Segment Dashboard
    6.2. Ophthalmic Clinical Trials Market, By Phase: Movement Analysis
    6.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    6.3.1. Discovery Phase
    6.3.1.1. Discovery Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    6.3.2. Preclinical Phase
    6.3.2.1. Preclinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    6.3.3. Clinical Phase
    6.3.3.1. Clinical Phase Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    Chapter 7. Ophthalmic Clinical Trials Market: Sponsor Type Estimates & Trend Analysis
    7.1. Ophthalmic Clinical Trials Market, By Sponsor Type: Segment Dashboard
    7.2. Ophthalmic Clinical Trials Market, By Sponsor Type: Movement Analysis
    7.3. Ophthalmic Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
    7.3.1. Pharmaceutical/biopharmaceutical Companies
    7.3.1.1. Pharmaceutical/biopharmaceutical Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    7.3.2. Medical Device Companies
    7.3.2.1. Medical Device Companies Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    7.3.3. Others
    7.3.3.1. Others Ophthalmic Clinical Trials Market 2018 to 2030 (USD Million)
    Chapter 8. Ophthalmic Clinical Trials Market: Regional Estimates & Trend Analysis
    8.1. Regional Market Share Analysis, 2022 & 2030
    8.2. Regional Market Dashboard
    8.3. Global Regional Market Snapshot
    8.4. North America
    8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    8.4.2. U.S.
    8.4.2.1. Key Country Dynamics
    8.4.2.2. Competitive Scenario
    8.4.2.3. Regulatory Framework
    8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    8.4.3. Canada
    8.4.3.1. Key Country Dynamics
    8.4.3.2. Competitive Scenario
    8.4.3.3. Regulatory Framework
    8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
    8.5. Europe
    8.5.1. UK
    8.5.1.1. Key Country Dynamics
    8.5.1.2. Competitive Scenario
    8.5.1.3. Regulatory Framework
    8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    8.5.2. Germany
    8.5.2.1. Key Country Dynamics
    8.5.2.2. Competitive Scenario
    8.5.2.3. Regulatory Framework
    8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    8.5.3. France
    8.5.3.1. Key Country Dynamics
    8.5.3.2. Competitive Scenario
    8.5.3.3. Regulatory Framework
    8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    8.5.4. Italy
    8.5.4.1. Key Country Dynamics
    8.5.4.2. Competitive Scenario
    8.5.4.3. Regulatory Framework
    8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    8.5.5. Spain
    8.5.5.1. Key Country Dynamics
    8.5.5.2. Competitive Scenario
    8.5.5.3. Regulatory Framework
    8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    8.5.6. Denmark
    8.5.6.1. Key Country Dynamics
    8.5.6.2. Competitive Scenario
    8.5.6.3. Regulatory Framework
    8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    8.5.7. Sweden
    8.5.7.1. Key Country Dynamics
    8.5.7.2. Competitive Scenario
    8.5.7.3. Regulatory Framework
    8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    8.5.8. Norway
    8.5.8.1. Key Country Dynamics
    8.5.8.2. Competitive Scenario
    8.5.8.3. Regulatory Framework
    8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
    8.6. Asia Pacific
    8.6.1. Japan
    8.6.1.1. Key Country Dynamics
    8.6.1.2. Competitive Scenario
    8.6.1.3. Regulatory Framework
    8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    8.6.2. India
    8.6.2.1. Key Country Dynamics
    8.6.2.2. Competitive Scenario
    8.6.2.3. Regulatory Framework
    8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    8.6.3. China
    8.6.3.1. Key Country Dynamics
    8.6.3.2. Competitive Scenario
    8.6.3.3. Regulatory Framework
    8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    8.6.4. South Korea
    8.6.4.1. Key Country Dynamics
    8.6.4.2. Competitive Scenario
    8.6.4.3. Regulatory Framework
    8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    8.6.5. Australia
    8.6.5.1. Key Country Dynamics
    8.6.5.2. Competitive Scenario
    8.6.5.3. Regulatory Framework
    8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    8.6.6. Thailand
    8.6.6.1. Key Country Dynamics
    8.6.6.2. Competitive Scenario
    8.6.6.3. Regulatory Framework
    8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
    8.7. Latin America
    8.7.1. Brazil
    8.7.1.1. Key Country Dynamics
    8.7.1.2. Competitive Scenario
    8.7.1.3. Regulatory Framework
    8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    8.7.2. Mexico
    8.7.2.1. Key Country Dynamics
    8.7.2.2. Competitive Scenario
    8.7.2.3. Regulatory Framework
    8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    8.7.3. Argentina
    8.7.3.1. Key Country Dynamics
    8.7.3.2. Competitive Scenario
    8.7.3.3. Regulatory Framework
    8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
    8.8. MEA
    8.8.1. South Africa
    8.8.1.1. Key Country Dynamics
    8.8.1.2. Competitive Scenario
    8.8.1.3. Regulatory Framework
    8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    8.8.2. Saudi Arabia
    8.8.2.1. Key Country Dynamics
    8.8.2.2. Competitive Scenario
    8.8.2.3. Regulatory Framework
    8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    8.8.3. UAE
    8.8.3.1. Key Country Dynamics
    8.8.3.2. Competitive Scenario
    8.8.3.3. Regulatory Framework
    8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    8.8.4. Kuwait
    8.8.4.1. Key Country Dynamics
    8.8.4.2. Competitive Scenario
    8.8.4.3. Regulatory Framework
    8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
    Chapter 9. Competitive Landscape
    9.1. Market Participant Categorization
    9.1.1. Innovators
    9.1.2. Market Leaders
    9.1.3. Emerging Players
    9.1.4. Company Market Share Analysis, 2022
    9.2. Company Profiles
    9.2.1. Charles River Laboratories International, Inc
    9.2.1.1. Company Overview
    9.2.1.2. Financial Performance
    9.2.1.3. Service Benchmarking
    9.2.1.4. Strategic Initiatives
    9.2.2. Laboratory Corporation of America Holdings
    9.2.2.1. Company Overview
    9.2.2.2. Financial Performance
    9.2.2.3. Service Benchmarking
    9.2.2.4. Strategic Initiatives
    9.2.3. IQVIA
    9.2.3.1. Company Overview
    9.2.3.2. Financial Performance
    9.2.3.3. Service Benchmarking
    9.2.3.4. Strategic Initiatives
    9.2.4. ICON Plc
    9.2.4.1. Company Overview
    9.2.4.2. Financial Performance
    9.2.4.3. Service Benchmarking
    9.2.4.4. Strategic Initiatives
    9.2.5. Vial
    9.2.5.1. Company Overview
    9.2.5.2. Financial Performance
    9.2.5.3. Service Benchmarking
    9.2.5.4. Strategic Initiatives
    9.2.6. Medpace
    9.2.6.1. Company Overview
    9.2.6.2. Financial Performance
    9.2.6.3. Service Benchmarking
    9.2.6.4. Strategic Initiatives
    9.2.7. ProTrials Research, Inc.
    9.2.7.1. Company Overview
    9.2.7.2. Financial Performance
    9.2.7.3. Service Benchmarking
    9.2.7.4. Strategic Initiatives
    9.2.8. Syneos Health
    9.2.8.1. Company Overview
    9.2.8.2. Financial Performance
    9.2.8.3. Service Benchmarking
    9.2.8.4. Strategic Initiatives
    9.2.9. Worldwide Clinical Trials, Inc
    9.2.9.1. Company Overview
    9.2.9.2. Financial Performance
    9.2.9.3. Service Benchmarking
    9.2.9.4. Strategic Initiatives
    9.2.10. ProRelix Services LLP.
    9.2.10.1. Company Overview
    9.2.10.2. Financial Performance
    9.2.10.3. Service Benchmarking
    9.2.10.4. Strategic Initiatives

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings